がん生物製剤市場 - 世界の産業規模、シェア、動向、機会、予測、製品別：用途別、エンドユーザー別、地域別、競合別、2020年～2030年

世界のがん生物製剤の市場規模は、2024年に941億米ドルとなり、2030年までの予測期間のCAGRは7.17％と、目覚ましい成長が見込まれています。

がん生物製剤は、腫瘍学生物製剤またはバイオ医薬品としても知られ、がんの治療に使用される薬剤のクラス別です。これらの薬剤は従来の化学療法とは異なり、がんの成長、進行、拡大に関与する特定の分子や経路を標的とするように設計されています。がん生物製剤は生きた細胞や生物に由来することが多く、モノクローナル抗体、サイトカイン、ワクチン、遺伝子治療薬など様々な治療薬が含まれます。これらの薬剤は、がん細胞の増殖と分裂を促進するシグナルを阻害します。腫瘍の成長を遅らせ、腫瘍に栄養を供給する新しい血管の形成を阻止するために使用されます。これらのモノクローナル抗体は、2つの異なる標的（多くの場合、1つはがん細胞上、もう1つは免疫細胞上）に同時に結合することができます。これらの抗体は、免疫系とがん細胞を近接させ、免疫反応を増強します。がん生物製剤は、がん細胞と健常細胞の両方に作用する従来の化学療法よりも、より標的が絞られ特異的であると考えられることが多いです。これらは、患者の免疫系を利用してがんと闘う、より広範な免疫療法の一分野です。例えば、WHOの予測によると、2022年には約2,000万人が新たにがんに罹患し、970万人が死亡すると推定されています。また、がんと診断されてから5年後に生存している人は5,350万人と予測されました。5人に1人が一生の間にがんを経験し、男性の約9人に1人、女性の約12人に1人ががんで死亡すると予想されています。肺がんは依然として最も罹患率が高く、世界で250万人の新規罹患者、つまり全新規罹患者の12.4％を占めています。肺がんの次に多いのは、前立腺がん（150万例、7.3％）、胃がん（97万例、4.9％）、結腸がん（190万例、9.6％）、女性の乳がん（230万例、11.6％）です。

バイオテクノロジーと免疫学の分野における継続的な研究開発と技術革新により、より効果的で標的を絞ったがん生物製剤が開発されています。新たな発見と技術の進歩が市場を前進させ続けています。個別化医療の動向は、特定の遺伝子変異やバイオマーカーを標的とする生物学的製剤の開発につながり、個々のがん患者に合わせた治療選択肢を提供しています。免疫チェックポイント阻害剤は、さまざまながん種で顕著な成功を収めており、現在進行中の調査では、さらなるがんへの応用が検討されており、市場の成長を牽引しています。定評のあるがん生物製剤に対するバイオシミラーの開発・承認により競争が激化し、コスト削減の可能性が市場の成長を促しています。がん患者支援団体や社会的認知度の向上により、革新的な治療や新規生物製剤の開発に対する需要が高まっています。製薬企業はがん研究開発に多額の投資を行い、新たな生物学的製剤や治療標的の発見につなげています。2024年3月、Zydus Lifescienceは、PARP阻害剤であるオラパリブをIBYRAのブランド名で発売し、インドの誰もが高度ながん治療を受けられるようにしました。ポリADPリボースポリメラーゼ（PARP）は、傷ついた細胞の修復を助けるタンパク質です。PARP阻害剤は、がん細胞におけるこの修復プロセスを阻害することで作用し、細胞死に導きます。

主要な市場促進要因

がん領域への投資の増加

認知度の向上と患者の支持

主要な市場課題

高い開発コスト

耐性と反応のばらつき

主要な市場動向

モノクローナル抗体の進歩

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のがん生物製剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（モノクローナル抗体、サイトカイン免疫療法、がんワクチン、CAR-T細胞療法、免疫チェックポイント阻害剤）
  • 用途別（非小細胞肺がん、前立腺がん、乳がん、急性骨髄性白血病、リンパ腫、その他）
  • エンドユーザー別（病院・診療所、外来診療センター、その他）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 アジア太平洋のがん生物製剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 用途別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州のがん生物製剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 用途別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米のがん生物製剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 用途別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米のがん生物製剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 用途別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのがん生物製剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 用途別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のがん生物製剤市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Roche Holding AG
• Novartis AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Amgen Inc.
• Johnson & Johnson
• Pfizer Inc.
• AstraZeneca plc
• Eli Lilly and Company
• AbbVie Inc.

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Cancer Biologics Market was valued at USD 94.10 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.17% through 2030F. Cancer biologics, also known as oncology biologics or biopharmaceuticals, are a class of drugs used to treat cancer. These drugs are distinct from traditional chemotherapy and are designed to target specific molecules and pathways involved in the growth, progression, and spread of cancer. Cancer biologics are often derived from living cells or organisms and include a variety of therapeutic agents, such as monoclonal antibodies, cytokines, vaccines, and gene therapies. These drugs inhibit the signals that promote the growth and division of cancer cells. They can be used to slow tumor growth and prevent the formation of new blood vessels that feed the tumor. These monoclonal antibodies can simultaneously bind to two different targets, often one on a cancer cell and one on an immune cell. They bring the immune system into proximity with cancer cells, enhancing the immune response. Cancer biologics are often considered more targeted and specific than traditional chemotherapy, which can affect both cancer and healthy cells. They are part of the broader field of immunotherapy, which harnesses the patient's immune system to fight cancer. For instance, according to WHO predictions, approximately 20 million new cancer cases and 9.7 million deaths from the disease were estimated to occur in 2022. It was also projected that 53.5 million people would be living five years after being diagnosed with cancer. One in five individuals is expected to experience cancer during their lifetime, with roughly 1 in 9 men and 1 in 12 women dying from the condition. Lung cancer remains the most prevalent, comprising 2.5 million new cases worldwide, or 12.4% of all new cases. Following lung cancer, prostate cancer (1.5 million cases, 7.3%), stomach cancer (970,000 cases, 4.9%), colon cancer (1.9 million cases, 9.6%), and female breast cancer (2.3 million cases, 11.6%) are the next most common.

Ongoing research and innovation in the field of biotechnology and immunology have led to the development of more effective and targeted cancer biologics. New discoveries and technological advancements continue to drive the market forward. The trend toward personalized medicine has led to the development of biologics that target specific genetic mutations and biomarkers, providing tailored treatment options for individual cancer patients. Immune checkpoint inhibitors have shown remarkable success in various cancer types, and ongoing research explores their application in additional cancers, driving market growth. The development and approval of biosimilars for established cancer biologics have increased competition and the potential for cost savings, encouraging market growth. Cancer patient advocacy groups and increased public awareness have led to a greater demand for innovative treatments and the development of new biologics. Pharmaceutical companies are investing significantly in oncology research and development, leading to the discovery of new biologics and therapeutic targets. In March 2024, Zydus Lifescience made advanced cancer treatment more accessible to everyone in India by introducing olaparib, a PARP inhibitor, under the brand name IBYRA. Poly-ADP ribose polymerase, or PARP, is a protein that helps injured cells repair themselves. PARP inhibitors work by inhibiting this repair process in cancer cells, leading to cell death.

Key Market Drivers

Rising Investment in Oncology

Higher investment in oncology research and development (R&D) has led to the discovery and development of new cancer biologics. Pharmaceutical and biotechnology companies allocate substantial funds to conduct clinical trials, explore innovative treatment modalities, and discover novel targets for biologic therapies. Increased funding has led to the discovery of new cancer targets and the development of biologics specifically designed to target these markers. This has expanded the range of available treatment options and personalized medicine approaches. Investment supports a growing number of clinical trials, including large-scale, multi-phase trials for cancer biologics. These trials are essential for evaluating the safety and efficacy of new treatments, ultimately leading to regulatory approvals. Investment has fueled the growth of biotechnology startups dedicated to oncology. These startups often focus on niche areas and novel biologic therapies, contributing to the diversity of treatment options. For instance, in April 2023, TORL BioTherapeutics LLC announced a $158 million Series B fundraising round and its public launch as a biopharmaceutical company focused on developing innovative biologics for cancer treatment. The company's antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) pipeline was discovered in the lab of scientific co-founder Dennis Slamon, who is a professor of medicine at UCLA's David Geffen School of Medicine (DGSOM) and serves as the chief of the hematology/oncology division.

Greater investment encourages innovation in biologics development. Researchers and companies explore novel therapeutic approaches, such as bispecific antibodies, gene editing technologies, and advanced immunotherapies. Investment in oncology research and development extends beyond well-established markets, offering cancer patients worldwide access to cutting-edge biologic treatments. Investment enables the exploration of combination therapies, where biologics are used in conjunction with other treatment modalities, such as chemotherapy, targeted therapies, or radiation therapy. These combinations have shown promise in enhancing treatment efficacy. Funding supports advancements in biologics manufacturing processes, making production more efficient, cost-effective, and scalable. This ensures a stable supply of these treatments. Ongoing investment in oncology leads to the exploration of biologics in new clinical indications and cancer types, broadening the market and increasing treatment options for patients. Funds are allocated to navigate the complex regulatory pathways associated with biologics, increasing the number of approved treatments available for patients. Investment in biomarker research and diagnostic tools enables a more targeted and personalized approach to cancer treatment. Biologics are often used in conjunction with companion diagnostics to identify the most appropriate therapy for individual patients. This factor will pace up the demand of the Global Cancer Biologics Market.

Increasing Awareness and Patient Advocacy

Patient advocacy groups and awareness campaigns provide valuable information about cancer biologics, their benefits, and their availability. This empowers patients and their families to make informed decisions about their treatment options. Increased awareness often leads to earlier cancer detection, which can result in a better prognosis and more treatment options, including biologics. Patients and their advocates often push for access to the latest and most advanced cancer treatments, including biologics. This demand can lead to changes in healthcare policies and increased funding for these therapies. Patients who are aware of clinical trials involving cancer biologics may be more willing to participate in research, helping to advance the development of new treatments and expand treatment options. Patient advocacy and awareness efforts have contributed to the push for personalized medicine. Patients and advocacy groups advocate for treatments tailored to individual genetics and biomarkers, which is a central feature of many biologic therapies. Increased awareness can lead to greater patient access to specialized clinics and healthcare providers experienced in administering cancer biologics. For instance, with an annual incidence of 2.24 million cases and a mortality rate of 1.80 million, lung cancer (LC) is the leading cause of cancer-related deaths worldwide. The two primary histological subtypes are non-small cell lung cancer (NSCLC), which accounts for 85% of cases, and small cell lung carcinoma (SCLC), making up 15% of all lung cancers.

Advocacy groups often raise funds for cancer research, including biologics development, through events, donations, and partnerships. This financial support helps drive further research and innovation. Increased awareness efforts aim to reduce the stigma surrounding cancer and cancer treatments, making it more acceptable for patients to explore various treatment options, including biologics. Advocacy groups often advocate for policy changes and regulatory reforms to improve the approval and accessibility of biologics, which can directly impact demand. Greater awareness can lead to higher enrollment in clinical trials, helping researchers gather valuable data on the efficacy and safety of biologic treatments, ultimately driving demand if positive results are achieved. By promoting early detection, personalized treatment, and advanced therapies like biologics, patient advocacy and awareness efforts contribute to improved patient outcomes, creating a growing demand for these treatments. Patient advocacy may focus on improving the quality of life for cancer patients. Biologics often have a more favorable side effect profile compared to traditional chemotherapy, making them a preferred choice for patients seeking a better quality of life during treatment. This factor will accelerate the demand of the Global Cancer Biologics Market.

Key Market Challenges

High Development Costs

Developing biologic therapies is a highly complex and resource-intensive process. It involves extensive preclinical research, clinical trials, and regulatory requirements, which all require substantial financial investments. Conducting clinical trials for cancer biologics, including Phase I, II, and III trials, is a costly endeavor. These trials involve patient recruitment, monitoring, data collection, and compliance with regulatory standards. Regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have stringent requirements for the approval of biologics. Meeting these standards necessitates significant investment in research and documentation. Biologics are challenging to manufacture due to their complexity. Establishing and maintaining the infrastructure for the large-scale production of biologics requires substantial capital. Maintaining the quality and consistency of biologics is vital to ensuring safety and efficacy. Stringent quality control and assurance processes contribute to development costs. Identifying appropriate biomarkers and targets for cancer biologics can be a resource-intensive process, requiring specialized research and expertise. Patient recruitment and ongoing monitoring in clinical trials involve substantial costs, including patient compensation, site expenses, and data management.

Resistance and Response Variability

Some cancer patients may exhibit innate or acquired resistance to certain biologics, meaning that the treatment may not be as effective as initially hoped. Tumors are often heterogeneous, with different regions of the tumor having distinct genetic profiles and responses to treatment. This heterogeneity can lead to resistance in certain tumor subpopulations. Patients can respond differently to biologic therapies due to factors such as genetics, overall health, and the presence of other medical conditions. This response variability can make it challenging to predict treatment outcomes accurately. The presence or absence of specific biomarkers, which are often used to select patients for certain biologics, can vary between individuals. This variability can impact the treatment's effectiveness. Cancer cells can adapt to treatment and develop resistance over time. This adaptability can lead to treatment failure and disease progression. Identifying the right patients for specific biologics based on predictive biomarkers is a complex process. Inadequate patient stratification can result in non-responders and treatment inefficiency. Developing and bringing new biologics to market is a costly and resource-intensive process. The potential for resistance and variability can increase the risks and costs associated with these endeavors.

Key Market Trends

Advancements in Monoclonal Antibodies

Monoclonal antibodies have been a cornerstone of cancer treatment for years, and ongoing advancements in this field are expanding their potential and impact. Bispecific monoclonal antibodies are designed to simultaneously target two different antigens or receptors, often present on cancer cells and immune cells. These bi-specific antibodies can enhance the immune system's ability to recognize and attack cancer cells, potentially leading to improved treatment outcomes. Immune checkpoint inhibitors are monoclonal antibodies that block proteins like PD-1 and PD-L1 to unleash the immune system's ability to attack cancer cells. Ongoing research is expanding the use of these inhibitors in various cancer types and as combination therapies. ADCs (Antibody-Drug Conjugates) are monoclonal antibodies that are chemically linked to cytotoxic drugs. These smart bombs selectively target cancer cells, delivering the drug payload directly to the tumor while sparing healthy tissue. Advancements in ADC technology have led to more effective and less toxic treatments. Researchers are continually identifying new cancer targets for monoclonal antibodies. This involves a deeper understanding of the molecular and genetic basis of cancer, leading to more precise targeting. Monoclonal antibodies are often used in combination with other immunotherapies or targeted therapies, leading to the development of innovative combination treatments to enhance treatment efficacy. Some monoclonal antibodies are being developed for subcutaneous administration, making treatment more convenient for patients compared to intravenous infusions. Advances in antibody engineering have led to the development of next-generation antibodies with enhanced properties, such as increased binding affinity, longer half-life, and improved tumor penetration. The identification of predictive biomarkers helps select patients who are most likely to respond to specific monoclonal antibody therapies, enabling a more personalized approach to treatment.

Segmental Insights

Application Insights

In 2024, the Global Cancer Biologics Market largest share was held by Acute Myeloid Leukemia segment and is predicted to continue expanding over the coming years. Cancer biologics play a crucial role in the treatment of breast cancer. These biologic therapies have been developed to target specific aspects of breast cancer biology, offering more targeted and effective treatment options. Human Epidermal Growth Factor Receptor 2 (HER2) is a protein that is overexpressed in some breast cancers. Biologics like trastuzumab (Herceptin) and pertuzumab (Perjeta) are monoclonal antibodies that specifically target HER2-positive breast cancers. They can block the growth signals of cancer cells and enhance the effectiveness of chemotherapy in these cases. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio), are used in combination with hormone therapy to treat hormone receptor-positive, HER2-negative metastatic breast cancer. These biologics inhibit specific proteins involved in cell division, slowing the progression of cancer. Some breast cancer patients benefit from immune checkpoint inhibitors, such as atezolizumab (Tecentriq) and pembrolizumab (Keytruda). These biologics unleash the immune system to attack cancer cells by blocking the immune checkpoints that prevent immune cells from recognizing and destroying cancer. Bevacizumab (Avastin) is a biologic antibody used to inhibit angiogenesis, the formation of new blood vessels that supply tumors with nutrients. It can be combined with chemotherapy to treat certain types of advanced breast cancer.a

End-User Insights

In 2024, the Global Cancer Biologics Market largest share was held by Hospitals & Clinics segment in the forecast period and is predicted to continue expanding over the coming years. Hospitals and clinics serve as primary points of access for cancer patients seeking diagnosis, treatment, and ongoing care. This results in a significant volume of cancer patients receiving biologics and other treatments within these healthcare settings. Hospitals and clinics offer comprehensive cancer care, including surgery, chemotherapy, radiation therapy, and biologics. They often have multidisciplinary teams of specialists who can coordinate and provide a range of treatments, including biologics, to address the complexity of cancer care. Healthcare professionals in hospitals and clinics have the expertise and experience required to administer biologics safely and effectively. They are equipped to handle the potential side effects and monitor patient responses. Many hospitals and academic medical centres actively participate in clinical trials and cancer research. This involvement allows them to offer patients access to cutting-edge biologics as part of clinical trial programs. Hospitals and clinics typically have advanced medical equipment and infrastructure necessary for the storage, preparation, and administration of biologics, which often require special handling and monitoring.

Regional Insights

The North America region dominated the Global Cancer Biologics Market in 2024. North America, particularly the United States and Canada, boasts highly advanced healthcare infrastructure and medical facilities. This allows for early diagnosis and effective treatment of cancer, including the use of biologics. The region is home to numerous leading biopharmaceutical companies, research institutions, and academic centers that are at the forefront of cancer biologics research and development. The United States has a well-established regulatory framework for the approval of biologics. The U.S. Food and Drug Administration (FDA) has a robust and transparent approval process that has encouraged the development and adoption of biologics. North America often serves as an early launch market for new biologics. This, in turn, leads to higher adoption rates and greater market share. Many global clinical trials for cancer biologics are conducted in North America, as it has a diverse and large patient population, streamlined regulatory processes, and skilled clinical trial infrastructure.

Key Market Players

• Roche Holding AG
• Novartis AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Amgen Inc.
• Johnson & Johnson
• Pfizer Inc.
• AstraZeneca plc
• Eli Lilly and Company
• AbbVie Inc.

Report Scope:

In this report, the Global Cancer Biologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Biologics Market, By Product:

• Monoclonal Antibodies
• Cytokine-Based Immunotherapy
• Cancer Vaccines
• CAR-T Cell Therapy
• Immune Checkpoint Inhibitors

Cancer Biologics Market, By Application:

• Non-small Cell Lung Cancer
• Prostate Cancer
• Breast Cancer
• Acute Myeloid Leukemia
• Lymphoma
• Others

Cancer Biologics Market, By End-User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Cancer Biologics Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Cancer Biologics Market.

Available Customizations:

Global Cancer Biologics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Biologics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, Immune Checkpoint Inhibitors)
  • 5.2.2. By Application (Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Cancer Biologics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Cancer Biologics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. India Cancer Biologics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Cancer Biologics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Cancer Biologics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product
      • 6.3.4.2.2. By Application
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Cancer Biologics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product
      • 6.3.5.2.2. By Application
      • 6.3.5.2.3. By End User

7. Europe Cancer Biologics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Cancer Biologics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Cancer Biologics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Cancer Biologics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Cancer Biologics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Cancer Biologics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. North America Cancer Biologics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Cancer Biologics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Cancer Biologics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Cancer Biologics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User

9. South America Cancer Biologics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cancer Biologics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Cancer Biologics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Cancer Biologics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Cancer Biologics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cancer Biologics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Cancer Biologics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Cancer Biologics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Cancer Biologics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Roche Holding AG
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Novartis AG
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Merck & Co., Inc.
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. Bristol-Myers Squibb Company
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. Amgen Inc.
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Johnson & Johnson
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Pfizer Inc.
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. AstraZeneca plc
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Eli Lilly and Company
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10. AbbVie Inc.
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer